Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics (DNLI) has disclosed Other Accumulated Expenses for 6 consecutive years, with $4.4 million as the latest value for Q4 2022.

  • Quarterly Other Accumulated Expenses fell 91.75% to $4.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2022, down 91.75% year-over-year, with the annual reading at $4.4 million for FY2022, 91.75% down from the prior year.
  • Other Accumulated Expenses for Q4 2022 was $4.4 million at Denali Therapeutics, down from $53.2 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $53.2 million in Q4 2021, with the low at $47000.0 in Q2 2018.
  • Average Other Accumulated Expenses over 5 years is $14.1 million, with a median of $3.5 million recorded in 2019.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 30801.59% in 2018, then plummeted 91.75% in 2022.
  • Over 5 years, Other Accumulated Expenses stood at $19.5 million in 2018, then increased by 23.36% to $24.0 million in 2019, then soared by 96.31% to $47.1 million in 2020, then increased by 12.77% to $53.2 million in 2021, then tumbled by 91.75% to $4.4 million in 2022.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $4.4 million, $53.2 million, and $47.1 million for Q4 2022, Q4 2021, and Q4 2020 respectively.